Prostate adenocarcinoma · line 2 · Radium-223 (mCRPC, bone-metastatic)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 2 |
|---|---|
| Track | standard |
| Linked regimen | REG-RADIUM223-MCRPC |
| ID | IND-PROSTATE-MCRPC-2L-RADIUM223 |
|---|---|
| Type | Indication |
| Status | reviewed 2026-05-04 | pending_clinical_signoff |
| Diseases | DIS-PROSTATE |
| Sources | SRC-ALSYMPCA-PARKER-2013 |
Used By
Algorithms
ALGO-PROSTATE-MCRPC-2L- ALGO-PROSTATE-MCRPC-2L